Clinical trials: Peripheral T Cells Lymphoma (PTCL)
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
Peripheral T Cell Lymphoma
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
This is a phase II open label, two-arm parallel design study of T-CHOP in patients with treatment naïve PTCL. Two doses of tenalisib (400 mg BID and 800 mg BID) will be evaluated in separate groups (Group 1: 400 mg BID and Group…
- Trial name
- NCT05239910
- Testing
- Tenalisib
- Where
- United States
- Sponsor
- Rhizen Pharmaceuticals SA
Peripheral T-Cell Lymphoma
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the overall response rate of KW-0761 for the treatment of patients with relapsed or refractory PTCL. KW-0761 targets CCR4.
- Trial name
- NCT01611142
- Testing
- KW-0761 (mogamulizumab)
- Where
- 15 sites in Denmark, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Peripheral T/NK Cell Lymphoma (R/R PTCL)
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
This is a Phase II, single-arm study to evaluate the efficacy, safety, and PK of oral linperlisib (YY-20394) monotherapy in adult patients with R/R Peripheral T/NK Cell Lymphoma.
- Trial name
- NCT05274997
- Testing
- YY-20394
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Relapsed or Refractory Lymphoma Including ENKL
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose…
- Trial name
- NCT06761677
- Testing
- Brincidofovir
- Where
- 8 sites in China, Japan and 1 more
- Volunteers
- 43 people
- Sponsor
- SymBio Pharmaceuticals
Relapsed/Refractory Peripheral T-cell Lymphoma
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined…
- Trial name
- NCT05403450
- Testing
- Tolinapant, Decitabine + Cedazuridine
- Where
- 19 sites in United States, Australia and 4 more
- Volunteers
- 33 people
- Sponsor
- Taiho Oncology, Inc.
Peripheral T-cell Lymphoma
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study.
- Trial name
- NCT01839097
- Testing
- Belinostat, CHOP
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- Acrotech Biopharma Inc.
Hodgkin Disease, Lymphoma, T-Cell, Peripheral
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06254495
- Testing
- PF-08046044/SGN-35C
- Where
- 33 sites in United States, Denmark and 4 more
- Volunteers
- 58 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Treatment-naïve, Peripheral T Cell Lymphoma
Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL
This is a multicentre, open-label, single-arm, phase Ib clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of liposomal mitoxantrone hydrochloride in combination with Cyclophosphamide, Vincristine…
- Trial name
- NCT04548700
- Testing
- Dose-finding stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone, Dose-expansion stage: Liposomal mitoxantrone hydrochloride, Cyclophosphamide, Vincristine and Prednisone
- Where
- China
- Volunteers
- 38 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non-Hodgkin Lymphoma
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma
- Trial name
- CERTAIN (NCT04526834)
- Testing
- CD30.CAR-T
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tessa Therapeutics
Hodgkin Disease, Peripheral T Cell Lymphoma
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT01716806
- Testing
- brentuximab vedotin, bendamustine, dacarbazine
- Where
- 54 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Seagen Inc.
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R…
- Trial name
- LuminICE-203 (NCT05883449)
- Testing
- AFM13, AB-101, Cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- Affimed GmbH
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL)
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies.
- Conditions
- Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL), Chronic Lymphocytic Leukemia (CLL)
- Trial name
- NCT04072458
- Testing
- L-Bcl-2 antisense oligonucleotide
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Bio-Path Holdings, Inc.
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
- Conditions
- Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS
- Trial name
- NAVAL-1 (NCT05011058)
- Testing
- Nanatinostat in combination with valganciclovir
- Where
- 62 sites in United States, Australia and 12 more
- Volunteers
- 102 people
- Sponsor
- Viracta Therapeutics, Inc.
Peripheral T Cell Lymphoma
A Study of Bosmolisib (BR101801) in Participants With R/R PTCL.
The objective of this phase II study is to evaluate the efficacy and safety of BR101801 in patients with peripheral T-cell lymphoma(PTCL).
- Trial name
- NCT07180771
- Testing
- BR101801
- Volunteers
- 44 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Peripheral T-Cell Lymphoma (PTCL)
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed peripheral…
- Trial name
- NCT02594267
- Testing
- Pralatrexate Injection
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Acrotech Biopharma Inc.
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Hematologic Malignancies, Solid Tumor
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Multicenter, open-label, phase 1a/1b trial of PF-07901800 (TTI-621) in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
- Trial name
- NCT02663518
- Testing
- PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
- Where
- 51 sites in United States, Canada
- Volunteers
- 249 people
- Sponsor
- Pfizer
Peripheral T Cell Lymphoma
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
- Trial name
- NCT04470141
- Testing
- SHC014748M treatment
- Volunteers
- 130 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.